Research progress in new drug targets for the treatment of pulmonary hypertension
Pulmonary hypertension(PH)is a complex cardiovascular disease with high mortality and disability rates.The utilization of PH-targeted drugs in China has enhanced patient survival rate.However,these drugs still possess limitations,such as low efficacy and obvious side effects.Recent research on the cause of PH has led to the discovery of new targets and pathways,offering hope for more treatment options.Clinical trials are underway for TLR3 agonist Poly(I∶C)and Corosolic acid,which target the STAT3 signaling pathway.These treatments may overcome the limitations of existing medications.Additionally,drugs used in other fields,such as ibuprofen and levosimendan,have shown potential as therapies for PH.This article reviewed current research on new target drugs to lay the groundwork for future research and development of therapeutic targets for PH.
万方数据
维普
